Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Biopharma Biotech Business Development
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Commercialization Consulting Resource Center
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
Biopharma Biotech Clinical trials
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Biopharma Biotech Clinical trials
Key market access considerations for long-acting and alternative delivery therapies Key market access considerations for long-acting and alternative delivery therapies
Blog February 20, 2026
Key market access considerations for long-acting and alternative delivery therapies
Biopharma Commercialization FDA
The market access “sweet spots” where payers reimburse more convenient therapies The market access “sweet spots” where payers reimburse more convenient therapies
Blog February 19, 2026
The market access “sweet spots” where payers reimburse more convenient therapies
Biopharma Commercialization Consulting Resource Center

Biopharma

Streamlining regulatory compliance with AI-enabled intelligence Streamlining regulatory compliance with AI-enabled intelligence
Blog September 2, 2025
Streamlining regulatory compliance with AI-enabled intelligence
New enrollment data shows health insurance disruption as more volatility approaches New enrollment data shows health insurance disruption as more volatility approaches
Blog July 2, 2025
New enrollment data shows health insurance disruption as more volatility approaches
These six radioligand therapy companies to watch are ushering in a new era of precision oncology These six radioligand therapy companies to watch are ushering in a new era of precision oncology
Blog June 18, 2025
These six radioligand therapy companies to watch are ushering in a new era of precision oncology
Pharma is placing bigger bets on fewer, more strategic assets/platforms Pharma is placing bigger bets on fewer, more strategic assets/platforms
Blog May 28, 2025
Pharma is placing bigger bets on fewer, more strategic assets/platforms
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
A closer look at four of this year’s Drugs to Watch A closer look at four of this year’s Drugs to Watch
Blog May 6, 2025
A closer look at four of this year’s Drugs to Watch
When weighing post-approval changes, many health authorities go it alone When weighing post-approval changes, many health authorities go it alone
Blog April 15, 2025
When weighing post-approval changes, many health authorities go it alone
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
This small biotech notched a big win for rare disease patients with a canny market access strategy This small biotech notched a big win for rare disease patients with a canny market access strategy
Blog December 19, 2024
This small biotech notched a big win for rare disease patients with a canny market access strategy
How J&J navigated regulatory approval for a Drug to Watch How J&J navigated regulatory approval for a Drug to Watch
Blog December 17, 2024
How J&J navigated regulatory approval for a Drug to Watch